𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?

✍ Scribed by Fabio Stagno; Paolo Vigneri; Francesco Di Raimondo

Book ID
117785574
Publisher
The Lancet
Year
2011
Tongue
English
Weight
37 KB
Volume
12
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Achievement of complete molecular respon
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease
✍ Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Michelina Santopietro; Ros πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 109 KB

Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cas